Valneva SE (INRLF)
OTCMKTS · Delayed Price · Currency is USD
5.75
0.00 (0.00%)
Aug 22, 2025, 4:00 PM EDT
Valneva SE Employees
Valneva SE had 713 employees as of December 31, 2024. The number of employees increased by 37 or 5.47% compared to the previous year.
Employees
713
Change (1Y)
37
Growth (1Y)
5.47%
Revenue / Employee
$329,380
Profits / Employee
-$112,475
Market Cap
1.01B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 713 | 37 | 5.47% |
Dec 31, 2023 | 676 | -43 | -5.98% |
Dec 31, 2022 | 719 | -43 | -5.64% |
Dec 31, 2021 | 762 | 262 | 52.40% |
Dec 31, 2020 | 500 | -21 | -4.03% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Glass House Brands | 374 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
Valneva SE News
- 5 days ago - Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older - GlobeNewsWire
- 11 days ago - Valneva SE 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 11 days ago - Valneva SE (VALN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Valneva reports 1H results; reaffirms FY outlook - Seeking Alpha
- 11 days ago - Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 16 days ago - FDA lifts pause on Valneva's chikungunya vaccine in elderly - Seeking Alpha
- 16 days ago - Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information - GlobeNewsWire
- 25 days ago - AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate - Business Wire